Long-term experience with levetiracetam

Epileptic Disorders

Volumn 5, Issue SUPPL. 1, 2003, Pages

  Abou Khalil, Bassel ^a   Lazenby, Barry ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

AEDs levetiracetam; Epilepsy; Long term therapy; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM;

AGGRESSIVENESS; AGITATION; ASTHENIA; BEHAVIOR DISORDER; CAUSE OF DEATH; DATA ANALYSIS; DEPRESSION; DRUG EFFICACY; DRUG INFORMATION; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EXPERIENCE; FOLLOW UP; HEADACHE; HUMAN; INFORMATION PROCESSING; INTRACTABLE PAIN; IRRITABILITY; LOW DRUG DOSE; MONOTHERAPY; MOOD; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SEIZURE; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SUICIDE; VERTIGO;

ANTICONVULSANTS; DRUG EVALUATION; DRUG THERAPY, COMBINATION; EPILEPSY; HUMANS; LONGITUDINAL STUDIES; PIRACETAM; PRODUCT SURVEILLANCE, POSTMARKETING; QUALITY OF LIFE; SEIZURES;

EID: 0038045660     PISSN: 12949361     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-42.
2. Shorvon SD, Löwenthal A, Janz D, et al. Multicenter doubleblind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000; 41: 1179-86.
3. Ben-Menachem E, Falter U, for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000; 41: 1276-83.
4. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000; 85: 77-85.
5. Krakow K, Walker M, Otoul C, et al. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 2001; 56: 1772-74.
6. Ben-Menachem E, Edrich P, Van Vleymen B, et al. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res 2003; 53: 57-64.
7. Cramer JA, Arrigo C, Van Hammée G, et al. Effect of levetiracetam on epilepsy-related quality of life. Epilepsia 2000; 41: 868-74.
8. Cramer J, Van Hammée G, Abou-Khalil BW. Long-term effects of levetiracetam on health-related quality of life. Epilepsia 2001; 42(Suppl 7): 245-6.
9. Wong ICK, Chadwick DW, Fenwick PBC, et al. The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. Epilepsia 1999; 40: 1439-45.
10. Sander JWAS, Trevisol-Bittencourt PC, Hart YM, et al. The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Res 1990; 7: 226-9.
11. Lhatoo SD, Wong ICK, Polizzi G, et al. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 2000; 41: 1592-96.
12. Lhatoo SD, Wong ICK, Sander JWAS. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia 2000; 41: 338-41.
13. Marson AG, Hutton JL, Leach JP, et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 2001; 6: 259-70.
14. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-9.